Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Down 22.1% in February

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) saw a significant decrease in short interest in February. As of February 13th, there was short interest totaling 7,474,168 shares, a decrease of 22.1% from the January 29th total of 9,597,134 shares. Approximately 10.9% of the shares of the stock are short sold. Based on an average daily volume of 2,061,707 shares, the days-to-cover ratio is currently 3.6 days. Based on an average daily volume of 2,061,707 shares, the days-to-cover ratio is currently 3.6 days. Approximately 10.9% of the shares of the stock are short sold.

Milestone Pharmaceuticals Price Performance

Shares of Milestone Pharmaceuticals stock remained flat at $1.65 on Wednesday. The stock had a trading volume of 729,640 shares, compared to its average volume of 1,455,675. The stock has a market cap of $140.53 million, a PE ratio of -2.01 and a beta of 0.48. The stock’s fifty day moving average is $1.89 and its 200-day moving average is $2.00. Milestone Pharmaceuticals has a fifty-two week low of $0.63 and a fifty-two week high of $3.06. The company has a quick ratio of 8.24, a current ratio of 8.24 and a debt-to-equity ratio of 2.74.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on MIST shares. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Milestone Pharmaceuticals in a report on Tuesday, January 6th. Zacks Research downgraded shares of Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. Wells Fargo & Company boosted their price objective on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Finally, Wall Street Zen cut Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Milestone Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $8.00.

Insiders Place Their Bets

In other news, insider Lorenz Muller sold 53,566 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $2.32, for a total value of $124,273.12. Following the completion of the sale, the insider directly owned 196,486 shares in the company, valued at $455,847.52. The trade was a 21.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Joseph Oliveto sold 34,523 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $1.93, for a total value of $66,629.39. Following the transaction, the chief executive officer directly owned 482,744 shares of the company’s stock, valued at approximately $931,695.92. The trade was a 6.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 416,327 shares of company stock valued at $935,458 in the last three months. 19.50% of the stock is currently owned by company insiders.

Institutional Trading of Milestone Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Propel Bio Management LLC increased its stake in shares of Milestone Pharmaceuticals by 186.1% in the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock worth $10,250,000 after acquiring an additional 3,333,333 shares during the last quarter. Orbimed Advisors LLC purchased a new stake in shares of Milestone Pharmaceuticals in the third quarter valued at about $6,444,000. Simplify Asset Management Inc. grew its holdings in shares of Milestone Pharmaceuticals by 186.2% in the third quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock valued at $5,666,000 after purchasing an additional 1,842,974 shares during the period. Marshall Wace LLP increased its position in Milestone Pharmaceuticals by 289.8% during the fourth quarter. Marshall Wace LLP now owns 1,656,821 shares of the company’s stock worth $3,347,000 after purchasing an additional 1,231,793 shares during the last quarter. Finally, Pathstone Holdings LLC purchased a new position in Milestone Pharmaceuticals during the third quarter worth about $2,000,000. 86.18% of the stock is currently owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.